Click Here for 5% Off Your First Aladdin Purchase!

Nicotinic acid - meets USP testing specifications, high purity , CAS No.59-67-6

  • PharmPure™
  • USP
Item Number
N433035
Grouped product items
SKUSizeAvailabilityPrice Qty
N433035-100g
100g
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$822.90

Basic Description

Synonymsnicotinic acid|niacin|59-67-6|Pyridine-3-carboxylic acid|3-pyridinecarboxylic acid|vitamin B3|3-Carboxypyridine|wampocap|Niaspan|Acidum nicotinicum|nicolar|Apelagrin|Pellagrin|Akotin|Daskil|Efacin|Pelonin|Linic|nicamin|nicobid|nicocap|Enduracin|Nicodelmin
Specifications & PurityPharmPure™, USP
Biochemical and Physiological MechanismsNicotinic modulates lipid metabolism and may be useful in treating dyslipidemia. It is an antioxidant and acts as a coenzyme in the form of nicotinamide adenine nucleotides. Deficiency of niacin leads to enhanced lipid peroxidation and is also implicated
GradePharmPure™, USP
Product Description

Gene Information

human ... CYP1A2(1544)rat ... Chrnb2(54239)


General Description

Nicotinic acid, also referred to as niacin or as vitamin B 3 , is a water-soluble vitamin. Nicotinic acid is synthesized from the amino acid tryptophan and is present majorly in peanuts, fish and lean meat.


Application

Nicotinic acid has been used as an antioxidant to evaluate its protective functionality in colon LoVo cell lines against doxorubicin induced cytotoxicity.

Associated Targets

CYP1A2 Tchem Cytochrome P450 1A2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DRD2 Tclin D(2) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DRD4 Tchem D(4) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CYP3A4 Tclin Cytochrome P450 3A4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ERBB2 Tclin Receptor tyrosine-protein kinase erbB-2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

GABRA1 Tclin Gamma-aminobutyric acid receptor subunit alpha-1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ELANE Tclin Neutrophil elastase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

EGFR Tclin Epidermal growth factor receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HMGCR Tclin 3-hydroxy-3-methylglutaryl-coenzyme A reductase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HDAC6 Tclin Histone deacetylase 6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HRH1 Tclin Histamine H1 receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLCO1B3 Tchem Solute carrier organic anion transporter family member 1B3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SLC6A4 Tclin Sodium-dependent serotonin transporter 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

SIGMAR1 Tclin Sigma non-opioid intracellular receptor 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PDE4D Tclin cAMP-specific 3',5'-cyclic phosphodiesterase 4D 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PTGS1 Tclin Prostaglandin G/H synthase 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CA2 Tclin Carbonic anhydrase 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

DRD3 Tclin D(3) dopamine receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

XDH Tclin Xanthine dehydrogenase/oxidase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CHRM3 Tclin Muscarinic acetylcholine receptor M3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CHRM4 Tclin Muscarinic acetylcholine receptor M4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA2B Tclin Alpha-2B adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA2C Tclin Alpha-2C adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR2A Tclin 5-hydroxytryptamine receptor 2A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA2A Tclin Adenosine receptor A2a 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ACHE Tclin Acetylcholinesterase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADRA1A Tclin Alpha-1A adrenergic receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AR Tclin Androgen receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MAOA Tclin Amine oxidase [flavin-containing] A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AKR1B1 Tclin Aldose reductase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

APP Tclin Amyloid-beta A4 protein 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA1 Tclin Adenosine receptor A1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR1A Tclin 5-hydroxytryptamine receptor 1A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ADORA3 Tchem Adenosine receptor A3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR3A Tclin 5-hydroxytryptamine receptor 3A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR6 Tchem 5-hydroxytryptamine receptor 6 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

HTR2B Tclin 5-hydroxytryptamine receptor 2B 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

EDNRA Tclin Endothelin-1 receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

EDNRB Tclin Endothelin receptor type B 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

KCNH2 Tclin Potassium voltage-gated channel subfamily H member 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRD1 Tclin Delta-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRK1 Tclin Kappa-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

OPRM1 Tclin Mu-type opioid receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NOS2 Tchem Nitric oxide synthase, inducible 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

TACR1 Tclin Substance-P receptor 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

NOS1 Tchem Nitric oxide synthase, brain 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name pyridine-3-carboxylic acid
INCHI InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)
InChi Key PVNIIMVLHYAWGP-UHFFFAOYSA-N
Canonical SMILES C1=CC(=CN=C1)C(=O)O
Isomeric SMILES C1=CC(=CN=C1)C(=O)O
RTECS QT0525000
Alternate CAS 59-67-6,99148-57-9 (tosylate)
PubChem CID 938
NSC Number 169454
MeSH Entry Terms 3 Pyridinecarboxylic Acid;3-Pyridinecarboxylic Acid;Aluminum Salt, Niacin;Enduracin;Hydrochloride, Niacin;Induracin;Lithium Nicotinate;Niacin;Niacin Aluminum Salt;Niacin Ammonium Salt;Niacin Calcium Salt;Niacin Cobalt (2+) Salt;Niacin Copper (2+) Salt;Nia
Molecular Weight 123.11
Beilstein 109591

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Chemical and Physical Properties

Flash Point(°C)193°C
Melt Point(°C)238°C

Safety and Hazards(GHS)

Pictogram(s) GHS07
Signal Warning
Hazard Statements

H319:Causes serious eye irritation

H412:Harmful to aquatic life with long lasting effects

Precautionary Statements

P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing.

P273:Avoid release to the environment.

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P501:Dispose of contents/container to ...

P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes.

P337+P317:If eye irritation persists: Get medical help.

RTECS QT0525000
Merck Index 6525

Related Documents

References

1. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S.  (2003)  PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect..  Nat Med,  (3): (352-5).  [PMID:12563315]
2. Richman JG, Kanemitsu-Parks M, Gaidarov I, Cameron JS, Griffin P, Zheng H, Guerra NC, Cham L, Maciejewski-Lenoir D, Behan DP et al..  (2007)  Nicotinic acid receptor agonists differentially activate downstream effectors..  J Biol Chem,  282  (25): (18028-36).  [PMID:17452318]
3. Jung JK, Johnson BR, Duong T, Decaire M, Uy J, Gharbaoui T, Boatman PD, Sage CR, Chen R, Richman JG et al..  (2007)  Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b..  J Med Chem,  50  (7): (1445-8).  [PMID:17358052]
4. Shen HC, Ding FX, Raghavan S, Deng Q, Luell S, Forrest MJ, Carballo-Jane E, Wilsie LC, Krsmanovic ML, Taggart AK et al..  (2010)  Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate..  J Med Chem,  53  (6): (2666-70).  [PMID:20184326]
5. Shen HC, Ding FX, Deng Q, Wilsie LC, Krsmanovic ML, Taggart AK, Carballo-Jane E, Ren N, Cai TQ, Wu TJ et al..  (2009)  Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats..  J Med Chem,  52  (8): (2587-602).  [PMID:19309152]
6. Skinner PJ, Webb PJ, Sage CR, Dang TH, Pride CC, Chen R, Tamura SY, Richman JG, Connolly DT, Semple G.  (2009)  5-N,N-Disubstituted 5-aminopyrazole-3-carboxylic acids are highly potent agonists of GPR109b..  Bioorg Med Chem Lett,  19  (15): (4207-9).  [PMID:19524438]
7. B Angelin,K Einarsson,B Leijd.  (1979-06-01)  Biliary lipid composition during treatment with different hypolipidaemic drugs..  European journal of clinical investigation,  ((3)): (185-190).  [PMID:113218]
8. J E Mrochek,R L Jolley,D S Young,W J Turner.  (1976-11-01)  Metabolic response of humans to ingestion of nicotinic acid and nicotinamide..  Clinical chemistry,  22  ((11)): (1821-1827).  [PMID:135660]
9. M R Stratford,M F Dennis,P Hoskin,H Phillips,R J Hodgkiss,A Rojas.  (1996-07-01)  Nicotinamide pharmacokinetics in humans: effect of gastric acid inhibition, comparison of rectal vs oral administration and the use of saliva for drug monitoring..  British journal of cancer,  74  ((1)): (16-21).  [PMID:8679452]
10. W G Brydon,H Nyhlin,M A Eastwood,M V Merrick.  (1996-02-01)  Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea..  European journal of gastroenterology & hepatology,  ((2)): (117-123).  [PMID:8723414]
11. Arthur S Brecher,Mohammed T Adamu.  (2002-04-18)  Short- and long-term effects of acetaldehyde on plasma..  Alcohol (Fayetteville, N.Y.),  26  ((1)): (49-53).  [PMID:11958947]
12. Beat Müller,Marlis Kasper,Christian Surber,Georgios Imanidis.  (2003-10-11)  Permeation, metabolism and site of action concentration of nicotinic acid derivatives in human skin. Correlation with topical pharmacological effect..  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,  20  ((2)): (181-195).  [PMID:14550884]
13. Nicholas B Pike.  (2005-12-03)  Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid..  The Journal of clinical investigation,  115  ((12)): (3400-3403).  [PMID:16322787]
14. Hong C Shen,Fa-Xiang Ding,Silvi Luell,Michael J Forrest,Ester Carballo-Jane,Kenneth K Wu,Tsuei-Ju Wu,Kang Cheng,Larissa C Wilsie,Mihajlo L Krsmanovic,Andrew K Taggart,Ning Ren,Tian-Quan Cai,Qiaolin Deng,Qing Chen,Junying Wang,Michael S Wolff,Xinchun Tong,Tom G Holt,M Gerard Waters,Milton L Hammond,James R Tata,Steven L Colletti.  (2007-11-13)  Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor..  Journal of medicinal chemistry,  50  ((25)): (6303-6306).  [PMID:17994679]
15. Vaijinath S Kamanna,Anthony Vo,Moti L Kashyap.  (2008-06-04)  Nicotinic acid: recent developments..  Current opinion in cardiology,  23  ((4)): (393-398).  [PMID:18520725]
16. Qiaolin Deng,Jessica L Frie,Daria M Marley,Richard T Beresis,Ning Ren,Tian-Quan Cai,Andrew K P Taggart,Kang Cheng,Ester Carballo-Jane,Junying Wang,Xinchun Tong,M Gerard Waters,James R Tata,Steven L Colletti.  (2008-09-02)  Molecular modeling aided design of nicotinic acid receptor GPR109A agonists..  Bioorganic & medicinal chemistry letters,  18  ((18)): (4963-4967).  [PMID:18760600]
17. H E Bays,D J Rader.  (2008-12-05)  Does nicotinic acid (niacin) lower blood pressure?.  International journal of clinical practice,  63  ((1)): (151-159).  [PMID:19054161]
18. Jason E Imbriglio,Sookhee Chang,Rui Liang,Subharekha Raghavan,Darby Schmidt,Abby Smenton,Scott Tria,Thomas O Schrader,Jae-Kyu Jung,Craig Esser,Andrew K P Taggart,Kang Cheng,Ester Carballo-Jane,M Gerard Waters,James R Tata,Steven L Colletti.  (2009-03-25)  GPR109a agonists. Part 1: 5-Alkyl and 5-aryl-pyrazole-tetrazoles as agonists of the human orphan G-protein coupled receptor GPR109a..  Bioorganic & medicinal chemistry letters,  19  ((8)): (2121-2124).  [PMID:19307116]
19. Janet E Digby,Justin M S Lee,Robin P Choudhury.  (2009-06-06)  Nicotinic acid and the prevention of coronary artery disease..  Current opinion in lipidology,  20  ((4)): (321-326).  [PMID:19494772]
20. Paul Martres.  (2009-06-13)  HM74a agonists: will they be the new generation of nicotinic acid?.  Current topics in medicinal chemistry,  ((5)): (428-435).  [PMID:19519459]
21. Caroline M Perry.  (2009-08-15)  Extended-release niacin (nicotinic acid)/laropiprant..  Drugs,  69  ((12)): (1665-1679).  [PMID:19678716]
22. Heinz Drexel.  (2009-08-18)  Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?.  Fundamental & clinical pharmacology,  23  ((6)): (687-692).  [PMID:19682084]
23. Naomi L Kruhlak,Sydney S Choi,Joseph F Contrera,James L Weaver,James M Willard,Kenneth L Hastings,Lawrence F Sancilio.  (2008-01-01)  Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models..  Toxicology mechanisms and methods,  18  ((2-3)): (217-227).  [PMID:20020916]
24. A Guerra,N E Campillo,J A Páez.  (2009-12-22)  Neural computational prediction of oral drug absorption based on CODES 2D descriptors..  European journal of medicinal chemistry,  45  ((3)): (930-940).  [PMID:20022146]
25. Darby Schmidt,Abigail Smenton,Subharekha Raghavan,Hong Shen,Fa-Xiang Ding,Ester Carballo-Jane,Silvi Luell,Tanya Ciecko,Tom G Holt,Michael Wolff,Andrew Taggart,Larissa Wilsie,Mihajlo Krsmanovic,Ning Ren,Daniel Blom,Kang Cheng,Peggy E McCann,M Gerard Waters,James Tata,Steven Colletti.  (2010-05-07)  Anthranilic acid replacements in a niacin receptor agonist..  Bioorganic & medicinal chemistry letters,  20  ((11)): (3426-3430).  [PMID:20444602]
26. Hans F N Kvitvang,Trygve Andreassen,Tomas Adam,Silas G Villas-Bôas,Per Bruheim.  (2011-03-11)  Highly sensitive GC/MS/MS method for quantitation of amino and nonamino organic acids..  Analytical chemistry,  83  ((7)): (2705-2711).  [PMID:21388201]
27. Minjun Chen,Vikrant Vijay,Qiang Shi,Zhichao Liu,Hong Fang,Weida Tong.  (2011-06-01)  FDA-approved drug labeling for the study of drug-induced liver injury..  Drug discovery today,  16  ((15-16)): (697-703).  [PMID:21624500]
28. Carol M Mason,Amy L Doneen.  (2011-08-02)  Niacin-a critical component to the management of atherosclerosis: contemporary management of dyslipidemia to prevent, reduce, or reverse atherosclerotic cardiovascular disease..  The Journal of cardiovascular nursing,  27  ((4)): (303-316).  [PMID:21804401]
29. Rachael Hartman,Taylor Defelice,Julia Tzu,Shane Meehan,Miguel Sanchez.  (2011-10-28)  Acanthosis nigricans in the setting of niacin therapy..  Dermatology online journal,  17  ((10)): (11-11).  [PMID:22031637]
30. Rahul Yadav,See Kwok,Basil J Ammori,Basil Issa,Handrean Soran.  (2011-12-03)  Safety and tolerability of extended-release niacin with laropiprant..  Expert opinion on drug safety,  11  ((1)): (151-159).  [PMID:22133050]
31. Andrew P Dunatchik,Matthew K Ito,Carlos A Dujovne.  (2012-03-06)  A systematic review on evidence of the effectiveness and\xa0safety of a wax-matrix niacin formulation..  Journal of clinical lipidology,  ((2)): (121-131).  [PMID:22385545]
32. Tai-Heng Chen,Clement Mtika.  (2012-11-02)  The peeling dermatitis with a peculiar demarcation..  The American journal of the medical sciences,  346  ((5)): (421-421).  [PMID:23114198]
33. U Julius,S Fischer.  (2013-01-30)  Nicotinic acid as a lipid-modifying drug--a review..  Atherosclerosis. Supplements,  14  ((1)): (7-13).  [PMID:23357134]
34. Ehab Haj Ali,Brittain McJunkin,Steven Jubelirer,William Hood.  (2013-02-19)  Niacin induced coagulopathy as a manifestation of occult liver injury..  The West Virginia medical journal,  109  ((1)): (12-14).  [PMID:23413541]
35. Wanda C Lakey,Nicole Greyshock,John R Guyton.  (2013-02-19)  Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrants..  Journal of clinical lipidology,  ((2)): (178-181).  [PMID:23415439]
36. .  (2013-03-08)  Drugs for hypertriglyceridemia..  The Medical letter on drugs and therapeutics,  55  ((1411)): (17-19).  [PMID:23467119]
37. Tom Noff,Jerald Insel.  (2013-04-06)  Energy drinks and the unwanted buzz: a case report..  Maryland medicine : MM : a publication of MEDCHI, the Maryland State Medical Society,  13  ((4)): (28-29).  [PMID:23556369]
38. N Nakajima,M Ueda,N Higashi,Y Katayama.  (2013-05-07)  Erythromelalgia associated with Clitocybe acromelalga intoxication..  Clinical toxicology (Philadelphia, Pa.),  51  ((5)): (451-454).  [PMID:23641936]
39. Miki Terakata,Tsutomu Fukuwatari,Eri Kadota,Mitsue Sano,Masaaki Kanai,Toshikazu Nakamura,Hiroshi Funakoshi,Katsumi Shibata.  (2013-05-24)  The niacin required for optimum growth can be synthesized from L-tryptophan in growing mice lacking tryptophan-2,3-dioxygenase..  The Journal of nutrition,  143  ((7)): (1046-1051).  [PMID:23700344]
40. Kambiz Zandi-Nejad,Ayumi Takakura,Mollie Jurewicz,Anil K Chandraker,Stefan Offermanns,David Mount,Reza Abdi.  (2013-07-25)  The role of HCA2 (GPR109A) in regulating macrophage function..  FASEB journal : official publication of the Federation of American Societies for Experimental Biology,  27  ((11)): (4366-4374).  [PMID:23882124]
41. Joy Wahawisan,John M Tovar,Mark C Granberry.  (2013-12-18)  Statin therapy: when to think twice..  The Journal of family practice,  62  ((12)): (726-732).  [PMID:24340334]
42. Hans-Michael Wolff,Irsan,Kalliopi Dodou.  (2014-03-07)  Investigations on the viscoelastic performance of pressure sensitive adhesives in drug-in-adhesive type transdermal films..  Pharmaceutical research,  31  ((8)): (2186-2202).  [PMID:24599801]
43. Alberto Zambon,Xue-Qiao Zhao,B Greg Brown,John D Brunzell.  (2014-03-20)  Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease..  The American journal of cardiology,  113  ((9)): (1494-1498).  [PMID:24641964]
44. Julio V Suarez,Stephen Banks,Paul G Thomas,Anil Day.  (2014-06-18)  A new F131V mutation in Chlamydomonas phytoene desaturase locates a cluster of norflurazon resistance mutations near the FAD-binding site in 3D protein models..  PloS one,  ((6)): (e99894-e99894).  [PMID:24936791]
45. Maria Angela Guzzardi,Leanne Hodson,Letizia Guiducci,Elena Sanguinetti,Pietro Di Cecco,Tiziana Liistro,Cristina Vassalle,Silvia Pardini,Lucia Giorgetti,Piero A Salvadori,Silvia Burchielli,Patricia Iozzo.  (2014-06-26)  Independent effects of circulating glucose, insulin and NEFA on cardiac triacylglycerol accumulation and myocardial insulin resistance in a swine model..  Diabetologia,  57  ((9)): (1937-1946).  [PMID:24962669]
46. Sofia Tapani,Joachim Almquist,Jacob Leander,Christine Ahlström,Lambertus A Peletier,Mats Jirstrand,Johan Gabrielsson.  (2014-07-06)  Joint feedback analysis modeling of nonesterified fatty acids in obese Zucker rats and normal Sprague-Dawley rats after different routes of administration of nicotinic acid..  Journal of pharmaceutical sciences,  103  ((8)): (2571-2584).  [PMID:24986056]
47. Donald M Lloyd-Jones.  (2014-07-12)  Niacin and HDL cholesterol--time to face facts..  The New England journal of medicine,  371  ((3)): (271-273).  [PMID:25014692]
48. Michael McCarthy.  (2014-07-25)  Niacin fails to reduce vascular events in large randomised trial..  BMJ (Clinical research ed.),  349  (g4774-g4774).  [PMID:25055803]
49. Kristel Hälvin,Ildar Nisamedtinov,Toomas Paalme.  (2014-09-10)  Comparison of different extraction methods to determine free and bound forms of B-group vitamins in quinoa..  Analytical and bioanalytical chemistry,  406  ((28)): (7355-7366).  [PMID:25195054]
50. Mack Moyo,Stephen O Amoo,Adeyemi O Aremu,Jiří Gruz,Michaela Subrtová,Karel Doležal,Johannes Van Staden.  (2014-09-16)  Plant regeneration and biochemical accumulation of hydroxybenzoic and hydroxycinnamic acid derivatives in Hypoxis hemerocallidea organ and callus cultures..  Plant science : an international journal of experimental plant biology,  227  (157-164).  [PMID:25219317]
51. Anja Veronovski,Gabrijela Tkalec,Željko Knez,Zoran Novak.  (2014-09-27)  Characterisation of biodegradable pectin aerogels and their potential use as drug carriers..  Carbohydrate polymers,  113  (272-278).  [PMID:25256485]
52. K Maráková,J Piestanský,E Havránek,P Mikus.  (2014-10-03)  Simultaneous analysis of vitamins B in pharmaceuticals and dietary supplements by capillary electrophoresis hyphenated with triple quadrupole mass spectrometry..  Die Pharmazie,  69  ((9)): (663-668).  [PMID:25272936]
53. Robert T Burns,Jan A Pechenik,William J Biggers,Gia Scavo,Christopher Lehman.  (2014-11-13)  The B vitamins nicotinamide (B3) and riboflavin (B2) stimulate metamorphosis in larvae of the deposit-feeding polychaete Capitella teleta: implications for a sensory ligand-gated ion channel..  PloS one,  ((11)): (e109535-e109535).  [PMID:25390040]
54. Martin J Landray,Richard Haynes,Jane Armitage.  (2014-11-13)  Niacin for reduction of cardiovascular risk..  The New England journal of medicine,  371  ((20)): (1943-1944).  [PMID:25390748]
55. Christopher M Rembold.  (2014-11-13)  Niacin for reduction of cardiovascular risk..  The New England journal of medicine,  371  ((20)): (1940-1941).  [PMID:25390749]
56. Amit V Khera,Arman Qamar,Muredach P Reilly,Richard L Dunbar,Daniel J Rader.  (2014-11-30)  Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia..  The American journal of cardiology,  115  ((2)): (178-182).  [PMID:25432415]
57. Brian M De Borba,Richard F Jack,Jeffrey S Rohrer,Joan Wirt,Dongmei Wang.  (2014-12-03)  Simultaneous determination of total nitrogen and total phosphorus in environmental waters using alkaline persulfate digestion and ion chromatography..  Journal of chromatography. A,  1369  (131-137).  [PMID:25441080]
58. Vladimir Tolstikov,Alexander Nikolayev,Sucai Dong,Genshi Zhao,Ming-Shang Kuo.  (2014-12-09)  Metabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cells..  PloS one,  ((12)): (e114019-e114019).  [PMID:25486521]
59. Won Seok Yang,Hyun Woo Kim,Joo Mi Lee,Nam Jeong Han,Mee Jeong Lee,Su-Kil Park.  (2015-01-04)  1,25-dihydroxyvitamin D3 causes ADAM10-dependent ectodomain shedding of tumor necrosis factor receptor 1 in vascular smooth muscle cells..  Molecular pharmacology,  87  ((3)): (533-542).  [PMID:25556238]
60. Rohini Sidhu,Hui Jiang,Nicole Y Farhat,Nuria Carrillo-Carrasco,Myra Woolery,Elizabeth Ottinger,Forbes D Porter,Jean E Schaffer,Daniel S Ory,Xuntian Jiang.  (2015-04-14)  A validated LC-MS/MS assay for quantification of 24(S)-hydroxycholesterol in plasma and cerebrospinal fluid..  Journal of lipid research,  56  ((6)): (1222-1233).  [PMID:25866316]
61. Miao Hu,Ya-Ling Yang,Chi-Fai Ng,Chui-Ping Lee,Vivian W Y Lee,Hiroyuki Hanada,Daisaku Masuda,Shizuya Yamashita,Brian Tomlinson.  (2015-05-23)  Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia..  Medicine,  94  ((20)): (e881-e881).  [PMID:25997070]
62. Shobha H Ganji,Moti L Kashyap,Vaijinath S Kamanna.  (2015-05-31)  Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease..  Metabolism: clinical and experimental,  64  ((9)): (982-990).  [PMID:26024755]
63. Shuai Yang,Xitao Li,Nasui Wang,Guoshu Yin,Shuhua Ma,Yucai Fu,Chiju Wei,Yongsong Chen,Wencan Xu.  (2015-06-28)  GPR109A Expression in the Murine Min6 Pancreatic Beta Cell Line, and Its Relation with Glucose Metabolism and Inflammation..  Annals of clinical and laboratory science,  45  ((3)): (315-322).  [PMID:26116596]
64. Kana Arai,Hiroyuki Terashima,Sen-ichi Aizawa,Atsushi Taga,Atsushi Yamamoto,Kaname Tsutsumiuchi,Shuji Kodama.  (2015-08-11)  Simultaneous Determination of Trigonelline, Caffeine, Chlorogenic Acid and Their Related Compounds in Instant Coffee Samples by HPLC Using an Acidic Mobile Phase Containing Octanesulfonate..  Analytical sciences : the international journal of the Japan Society for Analytical Chemistry,  31  ((8)): (831-835).  [PMID:26256608]
65. Victoria G Pederick,Bart A Eijkelkamp,Stephanie L Begg,Miranda P Ween,Lauren J McAllister,James C Paton,Christopher A McDevitt.  (2015-08-21)  ZnuA and zinc homeostasis in Pseudomonas aeruginosa..  Scientific reports,  (13139-13139).  [PMID:26290475]
66. Philip J Skinner,Martin C Cherrier,Peter J Webb,Young-Jun Shin,Tawfik Gharbaoui,Andrew Lindstrom,Vu Hong,Susan Y Tamura,Huong T Dang,Cameron C Pride,Ruoping Chen,Jeremy G Richman,Daniel T Connolly,Graeme Semple.  (2007-09-07)  Fluorinated pyrazole acids are agonists of the high affinity niacin receptor GPR109a..  Bioorganic & medicinal chemistry letters,  17  ((20)): (5620-5623).  [PMID:17804224]
67. B Greg Brown,Xue-Qiao Zhao.  (2008-06-14)  Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk..  The American journal of cardiology,  101  ((8A)): (58B-62B).  [PMID:18375243]
68. Fa-Xiang Ding,Hong C Shen,Larrisa C Wilsie,Mihajlo L Krsmanovic,Andrew K Taggart,Ning Ren,Tian-Quan Cai,Junying Wang,Xinchun Tong,Tom G Holt,Qing Chen,M Gerard Waters,Milton L Hammond,James R Tata,Steven L Colletti.  (2010-05-11)  Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A..  Bioorganic & medicinal chemistry letters,  20  ((11)): (3372-3375).  [PMID:20452209]
69. Rahul Yadav,Michael France,Naveed Younis,Salam Hama,Basil J Ammori,See Kwok,Handrean Soran.  (2012-05-23)  Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety..  Expert opinion on pharmacotherapy,  13  ((9)): (1345-1362).  [PMID:22607011]
70. Joshua T Chai,Janet E Digby,Robin P Choudhury.  (2013-03-26)  GPR109A and vascular inflammation..  Current atherosclerosis reports,  15  ((5)): (325-325).  [PMID:23526298]
71. Amit V Khera,Parin J Patel,Muredach P Reilly,Daniel J Rader.  (2013-08-13)  The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality..  Journal of the American College of Cardiology,  62  ((20)): (1909-1910).  [PMID:23933538]
72. Thomas F Whayne.  (2014-04-09)  Role of nicotinic acid in atherosclerosis prevention..  JAMA internal medicine,  174  ((4)): (648-649).  [PMID:24711199]
73. Zhichao Liu,Qiang Shi,Don Ding,Reagan Kelly,Hong Fang,Weida Tong.  (2011-12-24)  Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)..  PLoS computational biology,  ((12)): (e1002310-e1002310).  [PMID:22194678]

Solution Calculators